Acetyl-TP53 (K370) Antibody

What is the functional significance of p53 acetylation at lysine 370?

Acetylation of p53 at lysine 370 (K370) represents a critical post-translational modification that specifically regulates p53's transcriptional activity in stress responses. This modification serves several key functions in cellular processes. First, K370 acetylation enables promoter-specific binding of p53 to certain target genes, particularly those involved in apoptosis like PERP and DR5. Second, this modification demonstrates remarkable specificity in gene regulation - while K370 acetylation is necessary for activating pro-apoptotic genes, it appears less critical for cell cycle arrest genes like p21 . Third, p53 acetylation at K370 is required for an efficient apoptotic response following UVB exposure, as demonstrated by reduced apoptotic capacity in K370R mutants .

Research has demonstrated that disruption of K370 acetylation by site-directed mutagenesis (K370R) significantly suppresses UVB-induced expression of specific p53-responsive genes and reduces cellular apoptosis, highlighting the importance of this modification in stress response pathways . This specific acetylation site thus represents a key regulatory mechanism for determining which subset of p53 target genes will be activated in response to particular cellular stresses.

How does p85α regulate p53 K370 acetylation?

The regulatory subunit of phosphatidylinositol-3-kinase, p85α, plays a critical role in mediating p53 acetylation at K370 specifically during the UVB response through several mechanistic pathways. First, p85α binds directly to the acetyltransferase p300 and promotes its interaction with p53, facilitating the acetylation process . Second, p85α facilitates the recruitment of the p53/p300 complex to specific promoter regions of p53 target genes, enabling site-specific transcriptional activation . Third, p85α demonstrates remarkable specificity, regulating acetylation at K370 without affecting other acetylation sites such as K379 (mouse) or K317 .

What experimental models best demonstrate the effects of p53 K370 acetylation?

Several experimental models effectively demonstrate the functional importance of p53 K370 acetylation, each with specific advantages for investigating different aspects of this modification. The UVB irradiation model provides an excellent system, as UVB exposure of cells induces robust p53 K370 acetylation with peak acetylation observed approximately 8 hours post-exposure, followed by a gradual decline to basal levels within 24 hours . This model allows for time-course studies of the acetylation process and subsequent gene activation.

Comparative studies using mouse embryonic fibroblasts (MEFs) have been particularly informative, especially when comparing wild-type and p85α-null MEFs to elucidate the role of K370 acetylation in apoptotic responses . These genetic approaches provide clear evidence for the specific pathways regulating this modification. Additionally, site-directed mutagenesis creating the K370R mutation (where lysine is replaced with arginine to prevent acetylation) offers a powerful tool to directly assess the functional consequences of losing this specific modification .

A comprehensive experimental approach would include: (1) exposure of cells to UVB radiation or other DNA-damaging agents, (2) monitoring p53 K370 acetylation kinetics through time-course analysis, (3) comparison of wild-type p53 versus K370R mutant responses, and (4) assessment of downstream target gene activation and cellular outcomes using techniques like qRT-PCR and apoptosis assays .

What are the optimal conditions for detecting p53 K370 acetylation by Western blot?

Detecting p53 K370 acetylation by Western blot requires careful optimization of several technical parameters to ensure specific and sensitive detection. For sample preparation, it's essential to preserve the acetylation status of proteins by including deacetylase inhibitors such as Trichostatin A (500nM) alongside protease and phosphatase inhibitors in lysis buffers . Treatment of cells with DNA-damaging agents like UVB radiation or etoposide (20μM), combined with deacetylase inhibitors, maximizes the K370 acetylation signal and provides clearer results .

For immunoprecipitation approaches, which offer enhanced sensitivity, researchers should either immunoprecipitate total p53 first and then probe with the acetyl-K370 specific antibody, or directly immunoprecipitate with the acetyl-K370 antibody to enrich for the modified form . When performing Western blotting, recommended antibody dilutions typically range from 1:1000 to 1:2000, and positive controls such as HepG2 cells treated with etoposide and Trichostatin A should be included .

For signal verification and specificity confirmation, inclusion of a K370R mutant serves as an excellent negative control . Comparison with untreated samples helps demonstrate induction of acetylation and confirms the specificity of the antibody for the acetylated form of p53 . These optimized conditions ensure reliable detection of this specific post-translational modification while minimizing background and non-specific signals.

How can I optimize immunofluorescence staining using Acetyl-TP53 (K370) antibodies?

Optimizing immunofluorescence staining with Acetyl-TP53 (K370) antibodies requires attention to several technical parameters to achieve clear visualization with minimal background. For fixation and permeabilization, paraformaldehyde fixation (typically 4%) preserves epitope structure, followed by permeabilization with 0.25% Triton X-100 in PBS to allow antibody access to nuclear proteins . Methanol fixation should be avoided as it can disrupt acetylation epitopes and lead to false-negative results.

Blocking and antibody incubation steps are critical for signal quality. Thorough blocking (5% BSA or normal serum) minimizes background signal. Typical antibody dilutions range from 1:50 to 1:200 for immunofluorescence applications, with overnight incubation at 4°C often yielding better signal-to-noise ratio than shorter incubations . Nuclear counterstaining with DAPI helps confirm the nuclear localization of acetylated p53, which is expected given its role as a transcription factor .

Treatment considerations significantly impact detection sensitivity. Pre-treatment of cells with acetylation inducers improves signal detection, particularly combined treatments with DNA damage agents (e.g., etoposide) and deacetylase inhibitors (e.g., Trichostatin A) . Finally, proper controls are essential for result validation, including slides with primary antibody omitted and known positive controls such as HepG2 cells treated with etoposide and Trichostatin A .

What stimuli or treatments effectively induce p53 K370 acetylation for experimental purposes?

Several treatments have been demonstrated to effectively induce p53 K370 acetylation, allowing researchers to study this modification under controlled conditions. DNA damage agents are particularly effective, with UVB radiation extensively validated as an inducer of K370 acetylation, showing peak acetylation approximately 8 hours post-exposure . Etoposide (20μM), a topoisomerase II inhibitor, also effectively induces p53 acetylation and is commonly used in experimental protocols . Other genotoxic agents like doxorubicin and cisplatin may also induce this modification through similar DNA damage response pathways.

Histone deacetylase (HDAC) inhibitors play a crucial role in enhancing detectable acetylation. Trichostatin A (TSA) used at 500nM prevents deacetylation, thereby increasing acetylated p53 levels . While TSA alone may induce some acetylation, combination treatments yield the strongest results. The combination of DNA damage agents with HDAC inhibitors produces the most robust induction of K370 acetylation - for example, etoposide (20μM) plus TSA (500nM) for 6 hours is particularly effective .

Molecular approaches offer alternative induction methods, including overexpression of acetyltransferases like p300 or p85α, which promotes p300-p53 interaction and subsequent acetylation . When designing experiments, it's important to consider treatment kinetics, as acetylation typically follows a time-dependent pattern - in UVB response, acetylation peaks around 8 hours and gradually decreases within 24 hours .

How can I distinguish between specific K370 acetylation and other p53 acetylation sites?

Distinguishing between acetylation at K370 and other p53 acetylation sites requires a multi-faceted approach to ensure specificity in detection and analysis. Antibody specificity is the first critical factor - researchers should use antibodies that specifically recognize acetylated K370, such as those described in the search results, which have been validated against other acetylation sites . These commercial antibodies are specifically designed to detect p53 only when acetylated at K370.

Mutational analysis provides definitive evidence of site specificity. The K370R mutant allows direct assessment of signals specifically dependent on K370 acetylation . Creating multiple mutants (e.g., K370R, K373R, K382R) can help distinguish the contributions of individual sites in the complex regulatory network of p53 modifications. Different stressors may induce distinct patterns of acetylation across various sites - for example, research shows that p85α depletion specifically impairs K370 acetylation without affecting K379 acetylation in response to UVB .

For absolute confirmation of site-specific acetylation, mass spectrometry approaches such as liquid chromatography-tandem mass spectrometry (LC-MS/MS) can precisely identify and quantify acetylation at specific lysine residues. Time-course experiments also help distinguish between acetylation sites, as different sites may show distinct temporal patterns following stimulation . Using these approaches in combination provides a comprehensive picture of site-specific acetylation and helps avoid misinterpretation of signals.

How should I normalize p53 K370 acetylation data when total p53 levels change?

Normalizing p53 K370 acetylation data when total p53 levels fluctuate requires careful methodological consideration to ensure accurate interpretation of results. The most reliable approach involves calculating the ratio of acetylated p53 (K370) to total p53 for each sample, which normalizes the acetylation signal to account for variations in total p53 protein levels . This normalization is critical because p53 levels often increase dramatically in response to stress, and without proper normalization, changes in acetylation might simply reflect changes in total protein rather than specific modification patterns.

For Western blotting applications, sequential immunoblotting represents an effective technique - probing first with acetyl-K370 specific antibody, then stripping and reprobing with total p53 antibody . Using image analysis software to quantify band intensities allows calculation of acetylation/total protein ratios. Alternatively, an immunoprecipitation approach can be employed by immunoprecipitating equal amounts of total p53 from each sample, then probing with acetyl-K370 antibody to detect the proportion of p53 that is acetylated .

The research presented in search result 1 demonstrates this approach by showing that while p53 accumulated at comparable levels in both wild-type and p85α-null cells after UVB exposure, K370 acetylation was specifically impaired in p85α-null cells . This illustrates how changes in acetylation can be distinguished from changes in total protein levels using appropriate normalization strategies.

What patterns of K370 acetylation might indicate functional versus dysfunctional p53 activity?

The patterns of K370 acetylation can provide valuable insights into the functional status of p53 in both normal and pathological contexts. In functional p53 signaling, several characteristic patterns emerge. First, inducible acetylation shows a rapid increase in K370 acetylation following appropriate cellular stress, followed by a gradual decrease as the response resolves - typically peaking around 8 hours and resolving within 24 hours after UVB exposure . Second, functional acetylation correlates with target gene activation, particularly those involved in apoptosis like PERP and DR5 .

In contrast, dysfunctional patterns of K370 acetylation may include constitutive acetylation without stress stimulus, which could indicate dysregulated p53 activity. Another concerning pattern is K370 acetylation that fails to correlate with downstream gene expression, suggesting a break in the signaling pathway . Altered kinetics, such as abnormally prolonged or abbreviated acetylation response compared to normal cells, may also indicate dysfunction in p53 regulatory mechanisms.

The relationship between K370 acetylation and other modifications is also informative. In normal function, there is an appropriate balance between K370 acetylation and other post-translational modifications . Disruption of this balance, such as acetylation without appropriate phosphorylation or vice versa, may indicate dysfunctional p53 activity. These patterns can provide diagnostic or prognostic information in cancer and other diseases where p53 function is compromised.

How does p53 K370 acetylation interact with other post-translational modifications?

The interaction between K370 acetylation and other post-translational modifications creates a complex regulatory network that fine-tunes p53 function in response to diverse cellular stresses. While research indicates that p85α depletion impairs K370 acetylation without affecting phosphorylation at Ser18 or Ser389, suggesting some independence between these modifications, the complete interplay between multiple modifications remains an active area of investigation . The modification status at one site can potentially influence modifications at other sites, creating a "p53 code" that determines functional outcomes.

K370 can potentially undergo multiple modifications, including acetylation, methylation, or ubiquitination, which may be mutually exclusive at a single site but work together across different residues. For example, acetylation at K370 may prevent ubiquitination at the same site, thereby stabilizing p53 while also activating specific transcriptional programs . The temporal order of modifications may also be critical, with phosphorylation events potentially preceding and facilitating subsequent acetylation.

Domain-specific effects represent another important aspect of this regulatory network. K370 acetylation may influence the conformation of p53, affecting modifications in other domains and explaining why K370 acetylation selectively affects certain promoters (like PERP) but not others (like p21) . Understanding these complex interactions requires integrative approaches that simultaneously monitor multiple modification sites while assessing functional outcomes like DNA binding, protein-protein interactions, and target gene expression.

How can ChIP-seq with Acetyl-TP53 (K370) antibodies identify specific genomic targets?

ChIP-seq using Acetyl-TP53 (K370) antibodies represents a powerful approach to identify the specific genomic targets of K370-acetylated p53, providing genome-wide insights into the selective gene regulation facilitated by this modification. Successful implementation requires careful experimental design, beginning with thorough antibody validation for ChIP applications. Appropriate controls, including IgG control, total p53 ChIP, and samples from cells expressing K370R mutant, are essential for distinguishing specific from non-specific signals .

The ChIP protocol must be optimized for detecting acetylated proteins, with particular attention to fixation conditions (typically formaldehyde treatment) to preserve protein-DNA interactions without disrupting the acetylation epitope. Sonication conditions should be adjusted to generate 200-500bp DNA fragments, and immunoprecipitation conditions optimized using the validated Acetyl-TP53 (K370) antibodies . Following standard library preparation and sequencing protocols, the data analysis pipeline should include alignment to the reference genome, peak calling, motif analysis to confirm p53 response element enrichment, and integration with gene expression data.

What methodological approaches can reveal the relationship between p85α and p53 K370 acetylation?

Investigating the relationship between p85α and p53 K370 acetylation requires sophisticated methodological approaches that examine both the physical interactions between these proteins and their functional consequences. Genetic manipulation models provide foundational insights - comparing wild-type and p85α-deficient cells allows assessment of K370 acetylation dependency on p85α presence . Rescue experiments reintroducing wild-type or mutant p85α can determine which domains are essential for promoting K370 acetylation.

Protein interaction studies offer direct evidence of the molecular mechanisms involved. Co-immunoprecipitation can detect physical interactions between p85α, p300, and p53, as demonstrated in previous research . Advanced techniques like proximity ligation assays can visualize these protein interactions in situ, providing spatial information about where in the cell these interactions occur. Domain mapping through mutational analysis can identify specific regions of p85α required for promoting p53 acetylation.

ChIP-based approaches provide insights into the functional consequences at the genomic level. Sequential ChIP can determine co-occupancy of p85α, p300, and acetylated p53 at specific promoters, while ChIP-qPCR focused on specific promoters (e.g., PERP vs. p21) can help understand gene selectivity . Functional response analysis using reporter assays or real-time monitoring of gene expression can demonstrate how the p85α-p53 interaction affects downstream cellular responses to stress.

What are the kinetics of p53 K370 acetylation and how can they be accurately measured?

Understanding the kinetics of p53 K370 acetylation requires precise temporal measurements using various methodological approaches that capture the dynamic nature of this modification. Based on available research, UVB-induced K370 acetylation follows a specific temporal pattern, peaking around 8 hours post-exposure and returning to basal levels within 24 hours . This pattern suggests that experimental designs should include appropriate time points (e.g., 0, 2, 4, 8, 12, 16, 24 hours) to capture the complete acetylation profile.

Quantitative Western blotting represents the most established method for measuring these kinetics. This approach involves sequential blotting for acetylated and total p53, with careful normalization to total p53 levels at each time point . For higher throughput, techniques like AlphaLISA or automated Western blot systems can process multiple time points efficiently. Flow cytometry with acetyl-specific antibodies enables single-cell analysis, revealing population heterogeneity in the acetylation response.

Parallel analysis of upstream and downstream events provides a comprehensive view of the entire pathway. Measuring p300 recruitment and activity kinetics alongside p53 acetylation helps establish causal relationships . Similarly, tracking binding of acetylated p53 to target promoters by ChIP and monitoring target gene expression kinetics by RT-qPCR reveals how the kinetics of acetylation translate into functional outcomes . This multi-faceted approach to kinetic analysis can reveal how quickly p53 becomes acetylated following stress, how long the modification persists, and how these kinetics correlate with downstream cellular responses.